Phase II study of R–CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study

Phase II study of R–CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study

Abstract Background The response rate and survival improvement for rituximab, a CD20-targeting monoclonal antibody, have been demonstrated in marginal zone lymphoma (MZL) as monotherapy and in combination with chemotherapeutic regimens, yet relapses still occur despite treatment completion. Thus, ex...

Full description

Bibliographic Details
Main Authors: Sung Yong Oh, Won Seog Kim, Jin Seok Kim, Seok Jin Kim, Dok Hyun Yoon, Deok-Hwan Yang, Won Sik Lee, Hyo Jung Kim, Ho-Young Yhim, Seong Hyun Jeong, Jong Ho Won, Suee Lee, Jee Hyun Kong, Sung-Nam Lim, Jun Ho Ji, Kyung A. Kwon, Gyeong-Won Lee, Jae Hoon Lee, Ho Sup Lee, Ho-Jin Shin, Cheolwon Suh
Format: Article
Language:English
Published: Wiley 2019-10-01
Series:Cancer Communications
Subjects:
Marginal zone
Lymphoma
Advanced stage
Rituximab
Cyclophosphamide
Vincristine
Online Access:http://link.springer.com/article/10.1186/s40880-019-0403-7

Internet

http://link.springer.com/article/10.1186/s40880-019-0403-7

Similar Items